Octant, a data-driven therapeutics company developing programmable biology and chemistry to build precision medicines for complex diseases, has raised $80 million in a Series B financing round led by Catalio Capital Management (Catalio).
The company has also established a Deep Mutational Scanning (DMS) biopharma partnership with Bristol Myers Squibb, and appointed biotech industry veteran Dean “Rick” Artis as its first Chief Scientific Officer and renowned scientist Feng Zhang to its Scientific Advisory Board.
In addition to Catalio, the Series B financing included participation from Bristol Myers Squibb, and existing investors Andreessen Horowitz Bio Fund, Allen & Co, and 50 Years VC. To date, Octant has raised $115 million in funding.
Catalio’s co-Founder and Managing Partner, George Petrocheilos, is joining Octant’s Board of Directors as a Director, and Catalio’s Head of Research, Dr. Diamantis Xylas, and Bristol Myers Squibb’s Head of Small Molecule Drug Discovery, Mike Ellis, are joining the Board as Board Observers.
